[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,408
  • Shares Outstanding, K 5,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,560 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.53
  • Number of Estimates 2
  • High Estimate $-1.42
  • Low Estimate $-1.65
  • Prior Year $-12.25
  • Growth Rate Est. (year over year) +87.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +32.00%
on 05/13/26
2.95 -10.51%
on 06/01/26
+0.30 (+12.82%)
since 05/12/26
3-Month
1.97 +34.01%
on 03/19/26
2.95 -10.51%
on 06/01/26
+0.59 (+28.78%)
since 03/12/26
52-Week
1.79 +47.49%
on 03/09/26
24.00 -89.00%
on 07/18/25
-14.07 (-84.20%)
since 06/12/25

Most Recent Stories

More News
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel...

MBRX : 2.64 (-2.22%)
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

- Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman...

MBRX : 2.64 (-2.22%)
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc....

MBRX : 2.64 (-2.22%)
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its...

MBRX : 2.64 (-2.22%)
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject...

MBRX : 2.64 (-2.22%)
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026...

MBRX : 2.64 (-2.22%)
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal...

MBRX : 2.64 (-2.22%)
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin”...

MBRX : 2.64 (-2.22%)
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant...

MBRX : 2.64 (-2.22%)
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate,...

MBRX : 2.64 (-2.22%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 2.94
2nd Resistance Point 2.87
1st Resistance Point 2.75
Last Price 2.64
1st Support Level 2.56
2nd Support Level 2.49
3rd Support Level 2.37

See More

52-Week High 24.00
Fibonacci 61.8% 15.52
Fibonacci 50% 12.90
Fibonacci 38.2% 10.27
Last Price 2.64
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.